Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13601244 | 0.95 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL13601206 | 0.95 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL13601172 | 0.94 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL13601177 | 0.93 | CALCRL (0.58) | CALCRLRAMP1 | |
| SCHEMBL13601022 | 0.92 | CALCRL (0.56) | CALCRLRAMP1 | |
| SCHEMBL13601143 | 0.92 | CALCRL (0.55) | CALCRLRAMP1 | |
| SCHEMBL13601096 | 0.92 | CALCRL (0.55) | CALCRLRAMP1 | |
| SCHEMBL13601178 | 0.92 | CALCRL (0.56) | CALCRLRAMP1 | |
| SCHEMBL13601174 | 0.91 | CALCRL (0.59) | CALCRLRAMP1 | |
| SCHEMBL13601173 | 0.91 | CALCRL (0.63) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625886-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7625886-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-20070099903-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099903-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| WO-2007045672-A1 | SELECTED CGRP ANTAGONISTS METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099903-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.